Third, ligand-mediated activation of ERBB3 has been shown to result in PI3K/AKT-mediated resistance to TKIs in a variety of cancers, including ERBB2-amplified breast cancer cells stimulated with ERBB3 ligands, NRG1 [74] or HRG [75]. This evidence concerns the gene HRG and breast carcinoma.